February 5, 2025
Hot News

An energy trap for tumor cells: Researchers find enzyme blockade halts liver cancer growth

MyBlueDots01 mins
Glycolysis is a central metabolic pathway by which cells obtain energy from sugar. Cancer cells in particular have long been thought to depend on the energy obtained through glycolysis, a phenomenon known as the Warburg effect. Today we know that cancer cells can use energy sources more flexibly than previously thought. Even when glycolysis is blocked, they survive by obtaining their energy through the respiratory chain.
Read More

Aardvark Therapeutics Appoints Renowned Biopharma Leaders Roy D. Baynes and Susan E. Graf to its Board of Directors

MyBlueDots01 mins
SAN DIEGO–(BUSINESS WIRE)–Aardvark Therapeutics, Inc. (Aardvark), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointments of Roy D. Baynes, M.D., Ph.D., and Susan E. Graf, RPh, MBA to its Board of Directors. Dr. Baynes was previously Chief Medical Officer and head of clinical development at Merck. Ms. Graf is currently a senior advisor a
Read More

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

MyBlueDots01 mins
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that its partner iECURE has reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study. ECUR-506 is iECURE’s in vivo gene insertion program
Read More

CorriXR Therapeutics Appoints Jan Case as Chief Operating Officer

MyBlueDots01 mins
NEWARK, Del.–(BUSINESS WIRE)– #CRISPR–CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer. With over 25 years of experience in the biotechnology and pharmaceutical sectors, Case has driven operational excellence and strategic growth. As president of Cellicon Valley Consulting, she helped biotech start-ups, especially in the
Read More

Space and time? Here’s how they interact in the brain

MyBlueDots01 mins
Imagine a swarm of fireflies, flickering lights on and off in the nighttime space. How does the human brain process and integrate information about duration and spatial position enabling this vision? This was the question addressed by Valeria Centanino, Gianfranco Fortunato, and Domenica Bueti from SISSA’s Cognitive Neuroscience group in their research published in Nature Communications.
Read More
Top